DOP2010000372A - Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados famarceuticos que las contienen - Google Patents

Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados famarceuticos que las contienen

Info

Publication number
DOP2010000372A
DOP2010000372A DO2010000372A DO2010000372A DOP2010000372A DO P2010000372 A DOP2010000372 A DO P2010000372A DO 2010000372 A DO2010000372 A DO 2010000372A DO 2010000372 A DO2010000372 A DO 2010000372A DO P2010000372 A DOP2010000372 A DO P2010000372A
Authority
DO
Dominican Republic
Prior art keywords
carbolactones
pregn
substituted
ring
family
Prior art date
Application number
DO2010000372A
Other languages
English (en)
Inventor
Katja Prelle
Steffen Borden
Joachim Kuhnke
Ludwig Zorn
Rolf Bohlmann
Sven Ring
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41061273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP2010000372A publication Critical patent/DOP2010000372A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refïere a pregn-4-en-21,17- carbolactonas sustituidas en el anillo C de 1a formula general I en donde R6-7 es un metileno en posiciön o y R9 es un átomo de hidrógeno y R11 es un átomo de bromo, cloro o fluor , o R9 y R11 son juntos un enlace. Los nuevos compuestos son antimineralocorticoides ges- tagénicos.
DO2010000372A 2008-06-02 2010-12-02 Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados famarceuticos que las contienen DOP2010000372A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008026793A DE102008026793A1 (de) 2008-06-02 2008-06-02 C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
DOP2010000372A true DOP2010000372A (es) 2010-12-31

Family

ID=41061273

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000372A DOP2010000372A (es) 2008-06-02 2010-12-02 Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados famarceuticos que las contienen

Country Status (29)

Country Link
US (1) US20110130371A1 (es)
EP (1) EP2297177B1 (es)
JP (1) JP2012528075A (es)
KR (1) KR20110020240A (es)
CN (1) CN102046646B (es)
AR (1) AR071984A1 (es)
AU (1) AU2009254266A1 (es)
BR (1) BRPI0913401A2 (es)
CA (1) CA2726855A1 (es)
CL (1) CL2009001342A1 (es)
CO (1) CO6321132A2 (es)
CR (1) CR11821A (es)
DE (1) DE102008026793A1 (es)
DO (1) DOP2010000372A (es)
EA (1) EA017570B1 (es)
EC (1) ECSP10010652A (es)
ES (1) ES2389237T3 (es)
HK (1) HK1156954A1 (es)
HN (1) HN2010002548A (es)
IL (1) IL209371A0 (es)
MA (1) MA32321B1 (es)
MX (1) MX2010013233A (es)
NZ (1) NZ589593A (es)
PE (1) PE20100154A1 (es)
SV (1) SV2010003748A (es)
TW (1) TW201000106A (es)
UY (1) UY31859A (es)
WO (1) WO2009146811A1 (es)
ZA (1) ZA201009097B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004248A1 (de) 2010-07-08 2012-01-12 Bayer Pharma Aktiengesellschaft MIKROBIOLOGISCHES VERFAHREN ZUR HERSTELLUNG VON 11α-HYDROXY-DROSPIRENON
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN102876582B (zh) * 2011-07-15 2015-01-07 复旦大学 金龟子绿僵菌突变株及其在甾体化合物羟化反应中的应用
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
CN105779553B (zh) * 2014-12-15 2020-10-27 天津金耀集团有限公司 新月弯孢霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物
CN105779555B (zh) * 2014-12-15 2021-02-02 天津金耀集团有限公司 犁头霉和节杆菌联合发酵制备11β-羟基-1,4-二烯-3,20-二酮甾体化合物
CN104862323B (zh) * 2015-06-02 2018-01-16 中国农业科学院生物技术研究所 修饰苯二酚类化合物的羟化酶基因

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3092628A (en) * 1959-05-29 1963-06-04 Merck & Co Inc Aldosterone antagonists
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3539558A (en) * 1968-08-09 1970-11-10 Searle & Co 3 - oxygenated 3 - (9alpha,11beta - dichloro-17beta- hydroxyandrosten - 17alpha-yl)propionic acid gamma-lactones and congeners
DE2453823C2 (de) * 1974-11-11 1984-08-09 Schering AG, 1000 Berlin und 4709 Bergkamen 11β,17α-Dihydroxy-15α,16α-methylen-1,4-pregnadien-3,20-dion
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
HUP0402466A2 (en) * 2004-11-30 2006-07-28 Richter Gedeon Vegyeszet Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
ATE403668T1 (de) * 2005-07-21 2008-08-15 Bayer Schering Pharma Ag Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
DE102006030416A1 (de) 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
ITMI20061802A1 (it) * 2006-09-22 2008-03-23 Antibioticos Spa Epossidazione di 17-oxo-15,16-metilen steroidi con ilidi di solfossonio

Also Published As

Publication number Publication date
HK1156954A1 (es) 2012-06-22
AR071984A1 (es) 2010-07-28
CL2009001342A1 (es) 2010-05-28
HN2010002548A (es) 2012-08-27
MA32321B1 (fr) 2011-05-02
CA2726855A1 (en) 2009-12-10
CR11821A (es) 2011-02-04
US20110130371A1 (en) 2011-06-02
CN102046646B (zh) 2013-03-27
EA017570B1 (ru) 2013-01-30
TW201000106A (en) 2010-01-01
SV2010003748A (es) 2011-04-06
CN102046646A (zh) 2011-05-04
EP2297177A1 (de) 2011-03-23
CO6321132A2 (es) 2011-09-20
PE20100154A1 (es) 2010-03-20
AU2009254266A1 (en) 2009-12-10
UY31859A (es) 2010-01-05
MX2010013233A (es) 2010-12-21
DE102008026793A1 (de) 2009-12-03
JP2012528075A (ja) 2012-11-12
WO2009146811A1 (de) 2009-12-10
IL209371A0 (en) 2011-01-31
BRPI0913401A2 (pt) 2015-11-24
KR20110020240A (ko) 2011-03-02
ECSP10010652A (es) 2011-01-31
EA201001861A1 (ru) 2011-08-30
ZA201009097B (en) 2012-05-01
NZ589593A (en) 2012-04-27
ES2389237T3 (es) 2012-10-24
EP2297177B1 (de) 2012-06-20

Similar Documents

Publication Publication Date Title
DOP2010000372A (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados famarceuticos que las contienen
CO2017013709A2 (es) Lactamas bicíclicas.
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
PH12015500263A1 (en) New bicyclic derivatives
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
UY32049A (es) Inhibidores de cmet
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
CR11524A (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
CR11866A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
DOP2009000264A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
CO6430428A2 (es) Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
PA8793101A1 (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
AR083301A1 (es) Uso de composiciones de halogeno organico para reducir las emisiones de mercurio durante la combustion de carbon
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
UY32623A (es) Derivados bicíclicos para afecciones asociadas al receptor de andrógenos
UY33428A (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparacion y su aplicacion en terapeutica
CR11449A (es) Productos intermedios gsm
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
CU20100235A7 (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, así como preparados farmacéuticos que las contienen
CR20130005A (es) Agentes terapéuticos 976